Lisata Therapeutics (LSTA) Competitors $2.64 -0.09 (-3.30%) As of 07/3/2025 02:11 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LSTA vs. TNYA, BYSI, OPTN, HURA, COYA, XBIT, MCRB, OCX, VIRI, and ORMPShould you be buying Lisata Therapeutics stock or one of its competitors? The main competitors of Lisata Therapeutics include Tenaya Therapeutics (TNYA), BeyondSpring (BYSI), OptiNose (OPTN), TuHURA Biosciences (HURA), Coya Therapeutics (COYA), XBiotech (XBIT), Seres Therapeutics (MCRB), OncoCyte (OCX), Virios Therapeutics (VIRI), and Oramed Pharmaceuticals (ORMP). These companies are all part of the "pharmaceutical products" industry. Lisata Therapeutics vs. Its Competitors Tenaya Therapeutics BeyondSpring OptiNose TuHURA Biosciences Coya Therapeutics XBiotech Seres Therapeutics OncoCyte Virios Therapeutics Oramed Pharmaceuticals Tenaya Therapeutics (NASDAQ:TNYA) and Lisata Therapeutics (NASDAQ:LSTA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, profitability, risk, dividends, valuation, media sentiment and earnings. Which has more volatility & risk, TNYA or LSTA? Tenaya Therapeutics has a beta of 3, meaning that its share price is 200% more volatile than the S&P 500. Comparatively, Lisata Therapeutics has a beta of 1.03, meaning that its share price is 3% more volatile than the S&P 500. Do analysts recommend TNYA or LSTA? Tenaya Therapeutics presently has a consensus price target of $6.25, suggesting a potential upside of 922.91%. Lisata Therapeutics has a consensus price target of $15.00, suggesting a potential upside of 468.18%. Given Tenaya Therapeutics' higher probable upside, analysts plainly believe Tenaya Therapeutics is more favorable than Lisata Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tenaya Therapeutics 0 Sell rating(s) 0 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 3.00Lisata Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is TNYA or LSTA more profitable? Lisata Therapeutics' return on equity of -61.37% beat Tenaya Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Tenaya TherapeuticsN/A -92.20% -74.53% Lisata Therapeutics N/A -61.37%-53.35% Do insiders and institutionals have more ownership in TNYA or LSTA? 90.5% of Tenaya Therapeutics shares are held by institutional investors. Comparatively, 8.9% of Lisata Therapeutics shares are held by institutional investors. 48.7% of Tenaya Therapeutics shares are held by insiders. Comparatively, 9.1% of Lisata Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Which has better valuation and earnings, TNYA or LSTA? Lisata Therapeutics has higher revenue and earnings than Tenaya Therapeutics. Lisata Therapeutics is trading at a lower price-to-earnings ratio than Tenaya Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTenaya TherapeuticsN/AN/A-$111.13M-$1.16-0.53Lisata Therapeutics$1M22.76-$19.99M-$2.30-1.15 Does the media favor TNYA or LSTA? In the previous week, Tenaya Therapeutics had 1 more articles in the media than Lisata Therapeutics. MarketBeat recorded 1 mentions for Tenaya Therapeutics and 0 mentions for Lisata Therapeutics. Tenaya Therapeutics' average media sentiment score of 0.67 beat Lisata Therapeutics' score of 0.00 indicating that Tenaya Therapeutics is being referred to more favorably in the media. Company Overall Sentiment Tenaya Therapeutics Positive Lisata Therapeutics Neutral SummaryTenaya Therapeutics beats Lisata Therapeutics on 8 of the 12 factors compared between the two stocks. Get Lisata Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LSTA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding LSTA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart LSTA vs. The Competition Export to ExcelMetricLisata TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$22.57M$2.91B$5.56B$9.03BDividend YieldN/A2.44%5.22%3.99%P/E RatioN/A21.7127.7120.25Price / Sales22.76241.84389.53161.89Price / CashN/A42.7336.8958.10Price / Book0.767.518.035.67Net Income-$19.99M-$55.14M$3.18B$249.21M7 Day Performance-5.71%4.61%2.93%3.28%1 Month Performance-1.86%0.90%1.72%3.95%1 Year Performance-24.79%5.40%34.39%20.98% Lisata Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)LSTALisata Therapeutics2.4988 of 5 stars$2.64-3.3%$15.00+468.2%-24.8%$22.57M$1M0.0030Gap DownTNYATenaya Therapeutics3.4553 of 5 stars$0.61-0.4%$6.25+926.3%-79.1%$99.07MN/A-0.53110News CoverageBYSIBeyondSpringN/A$2.46+4.5%N/A-8.2%$98.98MN/A0.0080Positive NewsOPTNOptiNose0.7246 of 5 stars$9.60flat$9.00-6.3%N/A$97.22M$81.86M-2.29190HURATuHURA Biosciences1.2462 of 5 stars$2.22-0.7%$12.67+471.9%N/A$96.31MN/A0.00N/AAnalyst RevisionGap UpCOYACoya Therapeutics2.3183 of 5 stars$5.73-0.3%$16.67+190.9%-3.6%$95.86M$3.55M-5.366Analyst ForecastXBITXBiotech0.461 of 5 stars$3.03+1.9%N/A-44.5%$92.23M$4.01M-2.34100News CoverageMCRBSeres Therapeutics3.5579 of 5 stars$10.53-5.2%$73.67+599.6%-30.1%$91.93M$126.32M-2.29330News CoveragePositive NewsOCXOncoCyte2.0082 of 5 stars$3.18+16.3%$6.06+90.9%+4.8%$90.80M$3.84M-0.90120VIRIVirios TherapeuticsN/A$4.71-1.3%$5.00+6.2%+1,977.0%$90.71MN/A-17.445ORMPOramed Pharmaceuticals0.2612 of 5 stars$2.19-2.9%N/A-14.7%$89.26M$2M-4.9710Gap Down Related Companies and Tools Related Companies Tenaya Therapeutics Competitors BeyondSpring Competitors OptiNose Competitors TuHURA Biosciences Competitors Coya Therapeutics Competitors XBiotech Competitors Seres Therapeutics Competitors OncoCyte Competitors Virios Therapeutics Competitors Oramed Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:LSTA) was last updated on 7/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredA new rule goes live in July — and the banks are quietly cashing inA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredDalio heeds Buffett’s warning… [$319 million stake in gold]Dalio bought a gold ETF… I don’t recommend that for the average retail investor. The real upside is in profita...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lisata Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lisata Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
